

## Research Article

# Obesity and Low-Grade Inflammation Increase Plasma Follistatin-Like 3 in Humans

Claus Brandt,<sup>1</sup> Maria Pedersen,<sup>1</sup> Anders Rinnov,<sup>1</sup> Anne S. Andreasen,<sup>1</sup> Kirsten Møller,<sup>1,2</sup> Pernille Hojman,<sup>1</sup> Bente K. Pedersen,<sup>1</sup> and Peter Plomgaard<sup>1,3</sup>

<sup>1</sup> Centre of Inflammation and Metabolism (CIM), The Centre for Physical Activity Research (CFAS), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark

<sup>2</sup> Neurointensive Care Unit, Department of Neuroanaesthesiology, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark

<sup>3</sup> Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

Correspondence should be addressed to Peter Plomgaard; [plomgaard@dadlnet.dk](mailto:plomgaard@dadlnet.dk)

Received 25 March 2014; Accepted 2 June 2014; Published 3 July 2014

Academic Editor: Jonathan Peake

Copyright © 2014 Claus Brandt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Rodent models suggest that follistatin-like 3 (fstl3) is associated with diabetes and obesity. In humans, plasma fstl3 is reduced with gestational diabetes. *In vitro*, TNF- $\alpha$  induces fstl3 secretion, which suggests a link to inflammation. **Objective.** To elucidate the association between plasma fstl3 and obesity, insulin resistance, and low-grade inflammation in humans. **Study Design.** Plasma fstl3 levels were determined in a cross-sectional study including three groups: patients with type 2 diabetes, impaired glucose tolerance, and healthy controls. In addition, lipopolysaccharide (LPS), TNF- $\alpha$ , or interleukin-6 (IL-6) as well as a hyperinsulinemic euglycemic clamp were used to examine if plasma fstl3 was acutely regulated in humans. **Results.** Plasma fstl3 was increased in obese subjects independent of glycemic state. Moreover, plasma fstl3 was positively correlated with fat mass, plasma leptin, fasting insulin, and HOMA B and negatively with HOMA S. Furthermore plasma fstl3 correlated positively with plasma TNF- $\alpha$  and IL-6 levels. Infusion of LPS and TNF- $\alpha$ , but not IL-6 and insulin, increased plasma fstl3 in humans. **Conclusion.** Plasma fstl3 is increased in obese subjects and associated with fat mass and low-grade inflammation. Furthermore, TNF- $\alpha$  increased plasma fstl3, suggesting that TNF- $\alpha$  is one of the inflammatory drivers of increased systemic levels of fstl3.

## 1. Introduction

Follistatin-like 3 (fstl3) is a circulating glycoprotein [1], which is highly expressed in the reproductive system, but fstl3 is also expressed in adipose tissue, pancreas, liver, and skeletal muscle [2, 3]. The only known function of fstl3 is to form high-affinity complexes with TGF- $\beta$  family members, most notably activin A and myostatin and thereby inhibiting their function [4, 5]. Previous human as well as animal studies indicate that the regulation of these two target proteins is altered with obesity, diabetes or both. Thus elevated levels of activin A are found in adipose tissue from obese humans [6]. Moreover, patients with type 2 diabetes have elevated serum levels of activin A which correlate with markers of insulin resistance [7, 8]. Myostatin levels are elevated in

serum from obese individuals [9] and patients with type 2 diabetes have elevated myostatin expression in the skeletal muscle tissue [10]. In prediabetic men, endurance training lowered myostatin in both serum and muscle [11].

In line with the impact of obesity and diabetes on activin and myostatin, reports from both human [12] and animal studies [13] suggest that fstl3 is involved in glucose metabolism and obesity. Thus, plasma fstl3 correlates inversely with the glucose concentration 1 hour after a 50 g oral glucose load in women whom later developed gestational diabetes. Additionally, low plasma fstl3 levels are associated with insulin resistance during pregnancy in humans and low plasma concentrations of fstl3 in the first trimester are associated with an increased risk of developing gestational diabetes [14]. In contrast, in obese leptin-deficient mice, fstl3

mRNA is increased in the subcutaneous adipose tissue [2] while *fstl3* knockout mice have reduced visceral fat and hepatic steatosis [15]. Altogether, *fstl3* could be involved in glucose metabolism and adipose tissue function.

Obesity and low-grade inflammation are tightly linked in humans [16, 17]. Inflammation may play a role in the regulation of *fstl3* as the *fstl3* promoter contains a NF- $\kappa$ B binding site, and *fstl3* protein is increased in response to TNF- $\alpha$  stimulation in HepG2 cells [18]. Interestingly, activin A, which *fstl3* inhibits, is a part of the proinflammatory response [19].

The present study aimed at unravelling if circulating *fstl3* is associated with and/or regulated by players in the metabolic syndrome, such as inflammatory mediators and insulin. Therefore, we studied *fstl3* in a human cross-sectional study including healthy controls, individuals with impaired glucose tolerance, and patients with type 2 diabetes. Given that TNF- $\alpha$  stimulates *fstl3* *in vitro* and given the elevated levels of TNF- $\alpha$  in patients with obesity and insulin resistance [16], we measured *fstl3* in response to *E. coli* lipopolysaccharide (LPS), TNF- $\alpha$ , and IL-6 infusions in humans. We hypothesized that *fstl3* in humans would increase with insulin resistance and/or obesity and in response to inflammation. Here we demonstrate that *fstl3* is elevated in obese subjects and that *fstl3* increases in response to inflammation.

## 2. Materials and Methods

**2.1. Cross-Sectional Study.** Data from the cross-sectional part of this paper has previously been published [20] with data from 187 subjects. In the present study plasma *fstl3* levels were measured in 200 subjects. The reason for the difference between the present and the previous papers with regard to *n*-value is that 13 persons were excluded in the first publication based on cognitive function. There is no data suggesting that *fstl3* has an impact on cognitive function. Accordingly, we included all 200 subjects.

In brief, subjects who participated in the study were recruited to the cross-sectional study in order to obtain three groups representing different levels of glucose tolerance: a group with normal glucose tolerance (CON), a group with impaired glucose tolerance (IGT), and a group of subjects with type 2 diabetes mellitus (T2DM). The three groups were defined based on the oral glucose tolerance test (OGTT) according to WHO criteria. Insulin sensitivity and pancreatic beta-cell function were calculated by using the homeostatic model assessment (HOMA S and HOMA B) as described [28]. Obesity was defined as having a BMI of more than 30 kg/m<sup>2</sup>. OGTT, medication, VO<sub>2max</sub>, and cytokine measurements were performed as described in [20]. Participants were allowed to take oral antidiabetic drugs but had to stop 1 week prior to the OGTT. After an overnight fast the participants reported to the laboratory for a general health examination; a blood sample was taken for measurement of fasting glucose, insulin C-peptide, TNF- $\alpha$ , IL-6, CRP, leptin, and adiponectin. This blood sample was also used for determination of *fstl3*. Dual-energy X-ray absorptiometry (DXA) was used to determine fat and lean mass as described

in [20]. The participants were recruited by advertisement in local newspapers, and 3 subjects were recruited from the Steno Diabetes Centre database. Exclusion criteria were treatment with insulin, recent or ongoing infections, history of malignant cancer and severe chronic inflammatory diseases, fasting glucose above 12 mmol/L, and a blood pressure above 180 mm Hg/110 mm Hg.

**2.2. Lipopolysaccharide (LPS) Bolus Injection.** Samples were retrieved from a study on the inflammatory response to LPS in T2DM compared to normal glucose tolerance [21–24]. Originally, the material included 23 healthy control subjects and 19 patients with type 2 diabetes [23]. Only samples from 12 healthy controls and 11 subjects with type 2 diabetes were available for the present study. Data on cytokine levels in response to LPS is shown in [23] (Figures 1(a)–1(c)).

In brief, subjects reported in the laboratory at 08:00 in the morning after an overnight fast and rested in the supine position while having catheters placed in antecubital veins for injection and blood sampling. An intravenous injection of *Escherichia coli* LPS (Lot G2 B274, United States Pharmacopeial Convention, Rockville, MD, USA) was administered at a dose of 0.3 ng/kg. Plasma *fstl3* was measured at time points 0, 2, 4, 6, and 8 hours.

**2.3. TNF- $\alpha$  Infusion.** The material has previously been presented [25, 26]. Originally the material included ten healthy male volunteers. Only samples from 8 volunteers were available for the present study.

In brief, subjects reported to the laboratory at 08:00 in the morning after an overnight fast and rested in the supine position while having catheters placed in antecubital veins for infusion and blood sampling [26]. Subjects received a 4-hour infusion of rhTNF- $\alpha$  (Beromun) 700 ng/m<sup>2</sup>·h<sup>-1</sup> (Boehringer-Ingelheim, Biberach an der Riss, Germany) and on a separate day a 4-hour infusion of 20% albumin (TNF- $\alpha$  vehicle). The two study days were separated by at least one week. During the TNF- $\alpha$  infusion plasma TNF- $\alpha$  level was elevated to approximately 16 pg/mL and remained constant during the 4 hours of infusion as shown in [26] (Figure 1(a)). *Fstl3* was measured at time points -2, 0, 1, 2, 3, and 4 hours.

**2.4. IL-6 Infusion.** The material has previously been presented [25, 27]. Six healthy male subjects participated in the study. In brief, subjects underwent a general health examination before participating [28]. Subjects reported in the laboratory at 08:00 in the morning after an overnight fast and rested in the supine position while having catheters placed in antecubital veins for infusion and blood sampling. Subjects received a 3-hour infusion of rhIL-6 (Sandoz, Basle, Switzerland) at a rate of 5 ug/h. During the infusion of rhIL-6 plasma IL-6 level was elevated to approximately 150 pg/mL as shown in [25] (Figure 1(a)). *Fstl3* was measured at time points 0 h, 1 h, 2 h, 3 h, 6 h, and 24 h.

**2.5. Hyperinsulinemic Euglycemic Clamp.** Six healthy men aged 28.8  $\pm$  2.5 years (mean  $\pm$  SD) and BMI 22  $\pm$  0.6 kg/m<sup>2</sup> (mean  $\pm$  SD) were recruited through local newspapers.




FIGURE 1: Plasma follistatin-like 3 in subjects with different glucose tolerance and in nonobese and obese subjects. (a) Plasma follistatin-like 3 (fsl3) subdivided by glycemic status (CON,  $n = 78$ ), impaired glucose tolerance (IGT,  $n = 58$ ), and patients with type 2 diabetes (T2DM,  $n = 64$ ). (b) Plasma fsl3 in obese ( $n = 97$ ) and nonobese subjects ( $n = 103$ ). (c) Subdividing the control (obese = 36; nonobese = 42), (d) the impaired glucose tolerant (obese = 39; nonobese = 19), and (e) patients with type 2 diabetes (obese = 28; nonobese = 36). Boxplot showing median value of plasma fsl3 with 25th and 75th quartiles whiskers represents maximum and minimum value of fsl3. \*\* indicates  $P < 0.01$ . \*\*\* indicates  $P < 0.001$ .

Subjects underwent a general health examination before participating. The participants reported in the laboratory at 08:00 the morning after an overnight fast and rested in the supine position. Two peripheral intravenous catheters were placed: one for infusion of insulin and glucose and one for blood sampling. Subjects received continuous 5-hour infusion of insulin (Actrapid, 100 IU/mL; Novo Nordisk, Bagsvaerd, Denmark) at  $0.05 \text{ U} \cdot \text{min}^{-1} \cdot \text{m}^{-2}$ . Blood glucose was measured at bedside and glucose was infused by a computer-controlled infusion pump at rates adjusted according to blood glucose levels in order to uphold euglycemia. Fstl3 was measured in plasma from samples at -15 minutes before the start of the clamp and at 45 min, 1 h 45 min, 2 h 45 min, 3 h 45 min, and 4 h 45 min relative to the start of the clamp.

All studies were approved by the ethical committee and performed in accordance with the Helsinki Declaration. Written consent was obtained from each subject prior to enrolment in the study.

**2.6. Measurement of Plasma Follistatin-Like 3.** In all studies, EDTA plasma was stored at  $-80^{\circ}\text{C}$ . Plasma obtained after LPS and TNF- $\alpha$  study, fstl3 was measured using an fstl3 duo kit from cat number DY 1288 from R&D Systems. This kit has previously been used by others [12] and at the time of analysis the only available kit. The kit was used according to the manufacturer's instructions. In the cross-sectional study, the IL-6 infusion study, and the insulin clamp study, fstl3 was measured using a newer kit from Human FLRG (Quantikine ELISA Kit DFLRG0) from R&D Systems. Calculation of interassay variation was done by having two different control samples (in duplicate) on each plate. Mean value of fstl3 was calculated for each control, for the 6 plates used to measure fstl3 in the cross-sectional study. CV was 6.5% for control 1 and 7.4% for control 2. Intra-assay was calculated as the average CV for all the duplicates on each plate, by all 6 plates given a CV of 2.8% for the newest kit. Interassay variation CV% for the kit used in the LPS and the TNF- $\alpha$  studies was 3.8% calculated for three plates. Intra-assay variation calculated for the three plates used in the LPS study was 4.0%.

**2.7. Leptin and Adiponectin Measurement.** Plasma adiponectin, both high and low molecular forms, and leptin levels were measured using an ELISA kit from MSD (Meso Scale Discovery, Gaithersburg, USA) according to the manufacturer's instructions. Interassay variability was, 9% for leptin, and 17% for adiponectin, and intra-assay variability was 4.7% for leptin and 3.4% for adiponectin.

### 3. Statistics

As in the original cross-sectional study [20] data is presented as median and 25th + 75th quartiles. As many of the variables were not normally distributed, nonparametric tests were used for statistical analysis. To test for differences between the 3 glycemic groups, controls, IGT, and type 2 diabetics, Kruskal-Wallis test was used, and when significantly different, Wilcoxon rank test was applied to test CON versus IGT

and CON versus T2DM corrected for multiple testing using Bonferroni correction. For differences between obese and nonobese, or between females and males, a Wilcoxon rank-sum test (two-sample) was applied. Correlations of fstl3 to different clinical markers were done using Spearman's correlations coefficient. All analyses on the cross-sectional study were done using SAS Software version 9.1 (SAS Institute).

In all infusion studies, plasma fstl3 is presented as geometric mean  $\pm$  standard error of the mean (SEM). The effect of time and group on fstl3 by LPS and TNF- $\alpha$  infusion was assessed using two-way ANOVA. The effect of IL-6 and hyperinsulinemia was assessed by one-way ANOVA using the Proc Mixed procedure, SAS 9.1. As a post hoc test a Tukey test was used. For all statistical tests,  $P < 0.05$  was considered statistically significant.

## 4. Results

**4.1. Subject Characteristics for the Cross-Sectional Study (Table 1).** As compared to healthy controls, patients with T2DM were older and had higher fasting insulin, glucose, C-peptide, and IL-6 levels, and lower adiponectin, HOMA S, HOMA B, and  $\text{VO}_{2\text{max}}$ . Subjects with IGT also had elevated fasting insulin, glucose, C-peptide, IL-6, and TNF- $\alpha$  levels and lower HOMA S and adiponectin levels compared to CON.

**4.2. Plasma Fstl3 Is Elevated in Obese Subjects Independent of Glucose Tolerance (Figures 1(a)-1(e)).** In the total study population of 200 subjects, median plasma fstl3 was 6244 ( $Q_{25}$  5425- $Q_{75}$  7276) pg/mL. Fstl3 did not differ between CON (6216 (5447-6884) pg/mL), IGT (6344 (5733-7319) pg/mL), and T2DM groups (6062 (5111-7503) pg/mL). However, fstl3 was elevated in obese ( $\text{BMI} > 30 \text{ kg/m}^2$ ) compared to nonobese subjects, both in the total group 6892 pg/mL (6031-7888 pg/mL) versus 5751 pg/mL (5081-6388 pg/mL) and within subgroups.

**4.3. Plasma Fstl3 Is Correlated with Markers of Obesity, Insulin Resistance, and Inflammation (Tables 2 and 3).** In all subjects combined ( $n = 200$ ), fstl3 correlated positively with age, weight ( $P < 0.001$ ), hip ( $P < 0.001$ ) and waist ( $P < 0.001$ ) circumference, BMI ( $P < 0.001$ ), whole body fat ( $P < 0.001$ ), and trunk fat mass ( $P < 0.001$ ) and negatively with height ( $P < 0.05$ ) and  $\text{VO}_{2\text{max}}$  ( $P < 0.001$ ) (Table 2). Fstl3 also correlated with weight, hip and waist circumference, BMI, whole body fat, and trunk fat mass in individual groups. In the nonobese subjects, fstl3 was positively correlated with age, whole body fat, fat-free mass, and trunk fat. Plasma fstl3 correlated with age, hip and waist circumferences, BMI, whole body fat, trunk fat, fat-free mass lean body mass, and fat-free mass and negatively with  $\text{VO}_{2\text{max}}$  in obese subjects.

Further analyses showed that plasma fstl3 was correlated with fasting plasma insulin, fasting C-peptide, and  $\beta$ -cell function assessed by HOMA B, but not with fasting glucose. Fstl3 correlated negatively with insulin sensitivity measured by HOMA S in all groups and in nonobese, but not in obese subjects.

TABLE 1: Subjects' characteristics.

	Control ( <i>n</i> = 78)	IGT ( <i>n</i> = 58)	TD2M ( <i>n</i> = 64)	One-way ANOVA
	Median (q <sub>25</sub> -q <sub>75</sub> )	Median (q <sub>25</sub> -q <sub>75</sub> )	Median (q <sub>25</sub> -q <sub>75</sub> )	
	42/36	32/26	26/38	0.189 <sup>§</sup>
Age (years)	53 (48–60)	53 (47–60)	58 (51–62)*	0.035
Weight (kg)	86.6 (74.7–109.3)	96.7 (80.6–114.1)	87.9 (79.9–103.4)	0.063
Height (m)	173 (164–182)	171 (164–182)	177 (166–181)	0.189
Hip (cm)	110 (101–118)	135 (105–124)	106 (100–114)	0.004
Waist (cm)	98 (89–115)	108 (97–122)*	102 (96–110)	0.022
BMI (kg/m <sup>2</sup> )	29.4 (24.4–35.2)	32.0 (28–37)**	28.6 (25.8–32.9)	0.003
Systolic BP (mmHg)	135 (126–150)	139 (130–153)	142 (132–151)	0.112
Diastolic BP (mmHg)	89 (79–86)	88 (84–98)	92 (85–97)	0.190
VO <sub>2max</sub> (mL/min/kg)	26.0 (20.2–35.0)	25.1 (20.5–29.2)	24.0 (18.5–26.3)*	0.029
Whole body fat (kg)	31.9 (20.4–40.6)	35 (29–45)*	28 (21.5–37.1)	0.005
Trunk fat mass (kg)	17.1 (10.4–22.9)	20.5 (17.2–26.1)**	17.3 (13.0–22.3)	0.003
Whole body fat-free mass (kg)	55.3 (42.4–64.1)	52.5 (44.3–65.3)	57.1 (45.9–65.9)	0.724
Insulin fasting (pM)	41.0 (21.0–57.0)	52.5 (36.0–88.0)**	59.5 (30.0–102.5)**	<0.001
Glucose fasting (mM)	5.5 (5.2–5.9)	6.1 (5.7–6.3)***	8.4 (7.1–9.8)***	<0.001
C-peptide (nM)	0.70 (0.53–0.89)	0.89 (0.70–1.18)***	1.0 (0.69–1.25)***	<0.001
HOMA B	57.3 (39.8–78.9)	62.1 (48.3–81.0)	31.4 (20.8–64.3)***	<0.001
HOMA S	140.9 (89.6–249.1)	99.5 (60.1–159.5)**	85.5 (52.5–160.7)**	<0.001
TNF- $\alpha$ (pg/mL)	2.34 (2.04–2.82)	2.65 (2.25–3.04)*	2.47 (2.12–3.45)	0.033
IL-6 (pg/mL)	1.51 (1.06–2.32)	2.01 (1.46–3.25)*	2.33 (1.29–4.05)**	0.007
Leptin (ng/mL)	10.8 (3.1–26.4)	15.3 (6.6–38.7)	7.8 (3.5–22.7)	0.033
Adiponectin (ug/mL)	15.4 (11.9–21.3)	12.2 (9.0–16.6)**	10.2 (7.5–14.7)***	<0.001

General description of the three glycemic groups. Data presented as median with 25 and 75 quartiles. The control group consisted of 78 subjects, the impaired glucose tolerance (IGT) of 58 subjects except for VO<sub>2max</sub> (*n* = 57), whole body fat % (*n* = 57), and whole body fat-free mass (*n* = 57), and the patients with type 2 diabetes (T2DM) of 64 except for hip (*n* = 63), waist (*n* = 63), whole body fat % (*n* = 63), and whole body fat-free mass (*n* = 63). HOMA2 S: homeostasis model assessment of insulin sensitivity. HOMA B: homeostasis model assessment of beta-cell function. BMI: body mass index. \*significantly different from the control group. \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001. Corrected for multiple testing using bonferroni. <sup>§</sup>Chi square test.

In all subjects combined, plasma fsl3 correlated with plasma TNF- $\alpha$  and IL-6 (*P* < 0.001). In patients with T2DM, fsl3 correlated with both TNF- $\alpha$  and IL-6, whereas fsl3 only correlated with IL-6 and not TNF- $\alpha$  in the control and the IGT groups (Table 2). The association with TNF- $\alpha$  and IL-6 was present in both obese and nonobese subjects.

Fsl3 correlated with leptin in all subjects and subgroups. No correlation was observed to adiponectin.

**4.4. Gender.** Plasma fsl3 was higher in females than in males. Females have higher circulating fsl3 compared to males Plasma fsl3 was higher in females 6618 (Q<sub>25</sub> 5769–Q<sub>75</sub> 7429) pg/mL *n* = 100 than in males, 5892 (Q<sub>25</sub> 5205–Q<sub>75</sub> 6824) pg/mL *n* = 100; (*P* = 0.0024). This differences were only evident in obese (*P* = 0.002), but not between nonobese females and males (*P* = 0.083) (data not shown). As stated in Table 1 gender distribution did not differ between the different glycemic groups or was there a different in gender distribution between obese and nonobese subjects (*P* = 0.6712 Chi-square).

**4.5. Plasma Fsl3 Increases in Response to Acute Inflammation (Figures 2(a)–2(c)).** As plasma fsl3 correlated with markers

of low-grade inflammation, we investigated if plasma fsl3 was acutely regulated by inflammation. In the LPS study [21, 23], patients with type 2 diabetes and healthy controls were administered an LPS bolus of 0.3 ng/kg, which induced an inflammatory response with increased body temperature, heart rate, neutrophil count, and TNF- $\alpha$  and IL-6 levels [23]. In both groups, LPS increased circulating fsl3 over the 8-hour intervention period, with the highest levels observed after 6 hours. The response to LPS did not differ between controls and patients with T2DM (Figure 2(a)).

Next, we investigated if plasma fsl3 was regulated directly by the proinflammatory cytokines TNF- $\alpha$  or IL-6. During TNF- $\alpha$  infusion plasma fsl3 increased significantly after 3 hours and increased further at 4 hours (Figure 2(b)). No acute effect on plasma fsl3 was observed during IL-6 infusion (Figure 2(c)). However, the 24-hour time point was modestly but significantly elevated compared to all other time points.

**4.6. Fsl3 in Response to a Hyperinsulinemic Euglycemic Clamp (Figure 3).** As fsl3 was strongly correlated to fasting insulin, we investigated the direct fsl3 response to a hyperinsulinemic euglycemic clamp. Plasma fsl3 was not changed in response to insulin.



TABLE 2: Correlation between plasma follistatin-like 3 and demographic and biochemical characteristics.

	Total ( <i>n</i> = 200)	Control ( <i>n</i> = 78)	IGT ( <i>n</i> = 58)	T2DM ( <i>n</i> = 64)
	Spearman's <i>r</i>	Spearman's <i>r</i>	Spearman's <i>r</i>	Spearman's <i>r</i>
Age (years)	0.197**	0.202	0.037	0.331**
Weight (kg)	0.318***	0.278*	0.364**	0.309*
Height (m)	-0.178*	-0.135	-0.162	-0.185
Hip (cm)	0.468***	0.428***	0.543***	0.453***
Waist (cm)	0.457***	0.372***	0.479***	0.557***
BMI (kg/m <sup>2</sup> )	0.477***	0.420***	0.547***	0.447***
Systolic BP (mmHg)	0.020	0.008	0.005	0.046
Diastolic BP (mmHg)	0.086	0.160	0.033	0.067
VO <sub>2max</sub> (mL/min/kg)	-0.347***	-0.425***	-0.146	-0.436***
Whole body fat (kg)	0.585***	0.560***	0.598***	0.624***
Trunk fat mass (kg)	0.558***	0.521***	0.585***	0.595***
Whole body fat-free mass (kg)	-0.055	-0.058	0.073	-0.113
Insulin (fasting) (pM)	0.448***	0.378***	0.415**	0.554***
Glucose (fasting) (mM)	0.007	0.054	0.020	-0.071
c-peptide (nM)	0.453***	0.409***	0.380**	0.598***
HOMA B	0.372***	0.398***	0.371**	0.455***
HOMA S	-0.433***	-0.368***	-0.376**	-0.566***
TNF- $\alpha$ (pg/mL)	0.362***	0.128	0.250	0.593***
IL-6 (pg/mL)	0.497***	0.371***	0.363**	0.695***
Leptin (pg/mL)	0.598***	0.614***	0.545***	0.629***
Adiponectin (ug/mL)	0.044	-0.018	-0.040	0.176

Spearman's correlation coefficient is given for each variable in all subjects and in the different glycaemia groups. Spearman's correlation coefficient is given for each variable. The whole study group included 200 subjects except for hip (*n* = 199), waist (*n* = 199), BMI (*n* = 199), VO<sub>2max</sub> (*n* = 199), whole body fat (*n* = 198), whole body fat-free mass (*n* = 198). The control group consisted of 78 subjects, the IGT of 58 subjects except for VO<sub>2max</sub> (*n* = 57), whole body fat (*n* = 57), whole body fat-free mass (*n* = 57), and the T2DM of 64 except for hip (*n* = 63), waist (*n* = 63), whole body fat (*n* = 63), and whole body fat-free mass (*n* = 63). HOMA S: homeostasis model assessment of insulin sensitivity. HOMA B: homeostasis model assessment of beta cell function. BMI: body mass index. \*indicates a significant correlation between plasma fsl3 and the given variable. \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001.

## 5. Discussion

In the present study, the plasma level of fsl3 is elevated in obese subjects independent of glycemic status and is associated with fat mass as well as with plasma TNF- $\alpha$ , a strong marker of inflammation. Moreover, fsl3 is directly induced by both LPS and TNF- $\alpha$  administration, indicating that systemic inflammation increases fsl3 and that this effect is mediated by TNF- $\alpha$ . Finally, although plasma fsl3 is associated with markers of glucose intolerance, fsl3 is not increased in IGT or T2DM, suggesting an indirect rather than a direct relationship between insulin resistance and fsl3. A hyperinsulinemic clamp failed to increase fsl3 in plasma, suggesting that this putative relationship is not mediated by insulin.

Activin A is modestly increased in plasma from type 2 diabetic patients [7] and correlated with clinical parameter of type 2 diabetes [8]. In continuation, a 35% increase in serum myostatin is observed in obese humans [9]. Furthermore, training results in a 22% reduction in serum myostatin [11] in middle age men. Thus, the 20% increase in plasma fsl3 reported here in obese compared to nonobese subjects indicates that regulation of the myostatin/activin A fsl3 system in humans results in relatively small changes in circulating levels.

The few previous studies of fsl3 in humans have mainly addressed changes occurring during pregnancy. Thus elevated levels of fsl3 have been observed in women with preeclampsia [29, 30] and low levels of plasma fsl3 have been reported in women with gestational diabetes [12, 14, 29]. Fsl3 is highly expressed in the placenta [31]. During preeclampsia and gestational diabetes the expression of fsl3 in placenta is increased and decreased, respectively [14, 29, 30]. This suggests that the placenta may contribute to circulating fsl3 during pregnancy making comparison to type 2 diabetes and obesity difficult. In line with our data, others have demonstrated that fsl3 correlates with age and body weight [32] and BMI [12]. The observation that fsl3 correlated with age may be related to the increase in the ligands of fsl3, activin A and myostatin, which are increased with age [19, 33].

**5.1. Fsl3 and Glucose Metabolism.** In the present study plasma fsl3 is not different between controls, IGT, or T2DM and shows no association with fasting glucose suggesting that fsl3 is not involved in insulin resistance. Furthermore plasma fsl3 is not increased in response to insulin, indicating that fsl3 is not regulated by insulin. We did find a positive correlation between plasma fsl3 and fasting insulin, C-peptide and a negative correlation to insulin sensitivity




FIGURE 2: Plasma follistatin-like 3 in response to an LPS bolus and infusion of TNF- $\alpha$  and IL-6. (a) Effect of intravenous lipopolysaccharide (LPS) bolus (0.3 ng/kg) on circulating fsl3 in healthy subjects ( $n = 12$ ) and patients with type 2 diabetes ( $n = 11$ ) at prior to and 2, 4, 6, and 8 hours following the LPS bolus. No difference between the two groups existed, but a significant time effect. Data is presented as mean  $\pm$  SEM. \*\*\* indicates a time effect  $P < 0.001$ , two-way ANOVA. (b) Effect of TNF- $\alpha$  infusion (700 ng/m<sup>2</sup>·h<sup>-1</sup>) on plasma fsl3. Two-way ANOVA: time  $P < 0.001$ , group  $P = 0.0012$  and time \*group  $P < 0.001$ . 2B. Data is presented as mean  $\pm$  SEM ( $n = 8$ ). #Significantly different from albumin infusion  $P < 0.01$ . ##  $P < 0.001$ . (c) The effect of IL-6 infusion (5 ug/h) on plasma fsl3. Data is presented as mean  $\pm$  SEM ( $n = 6$ ). \*\*\*Significantly different from time points 0.5, 1, 2, 3, and 6 hours, one-way ANOVA.

(HOMA S). Low plasma fsl3 is associated with greater risk of developing gestational diabetes as fsl3 correlates negatively with peak glucose levels during a 50 g oral glucose load [12]. In another report also on gestational diabetes, no correlation to insulin resistance (HOMA IR) could be demonstrated with plasma fsl3 [14]. The difference between our data and the gestational diabetes studies may be explained by contribution of fsl3 to the circulation by the placenta during pregnancy. Furthermore, this could indicate that low fsl3 and thereby a potentially higher myostatin and activin A levels in plasma could be involved in the development of insulin resistance. In support of this view is the observation that activin A [34] but not myostatin [14] is increased in gestational diabetes.

**5.2. Fsl3 and Adipose Tissue.** In the present study plasma fsl3 is elevated in obese subjects and fsl3 is positively

associated with total fat mass, trunk fat mass, and circulating leptin. Moreover, fsl3 is expressed in adipocytes and is increased in obese mice [2] and knockout of fsl3 in mice alters fat distribution [15]. Taken together this suggests that adipose tissue may contribute to circulating fsl3 levels. This is further supported by the finding that females, who generally have both higher fat percentage and leptin levels [35], also have higher fsl3 in plasma. As mentioned women with preeclampsia have elevated placental and plasma fsl3 levels [29, 30]. Leptin is also expressed by the placenta and plasma leptin levels are also increased in preeclampsia [36], which could indicate a common source or similar regulation of leptin and fsl3. Age is a possible confounder in the present study, as age is positively associated with plasma fsl3 in both nonobese and obese (Table 3). However nonobese subjects were older compared to the obese group (data not shown).




FIGURE 3: Plasma follistatin-like 3 during a hyperinsulinemic-euglycemic clamp. Plasma fstl3 during a hyperinsulinemic euglycemic clamp ( $0.05 \text{ U} \cdot \text{min}^{-1} \cdot \text{m}^{-2}$ ). Data is presented as mean  $\pm$  SEM. Fstl3 was not altered by insulin ( $P = 0.12$ ), one-way ANOVA ( $n = 6$ ).

This pattern was also present when the three glyceic groups were divided by obesity (data not shown). In the nonobese and obese groups 25 and 20 subjects were in treatment with statins, respectively. Therefore it is unlikely that plasma fstl3 is increased in the obesity group due to age or lipid lowering drugs.

**5.3. Fstl3 and Inflammation.** Exploring the association between fstl3 and low-grade inflammation observed in the cross-sectional study, by acute administration of LPS and TNF- $\alpha$ , we observed an increase of plasma fstl3 levels in humans. Activin A is well known for its acute proinflammatory actions as part of the innate immune system in response to LPS administration [37]. As fstl3 antagonizes activin A, the increase in fstl3 may potentially be considered a countercompensatory response to control the inflammatory process. This interpretation is consistent with the time course for plasma fstl3 in both the LPS and the TNF- $\alpha$  studies where fstl3 peaks later than activin A [37]. IL-6 does not acutely regulate fstl3 consistent with that IL-6 is not the driver for fstl3 during the LPS bolus. Fstl3 is increased after the IL-6 infusion at 24-hour time point compared with all other time points. The increase was modest before  $5090 \pm 227$  versus  $5657 \pm 372$  pg/mL at 24 hours. However, it is possible that IL-6 may increase fstl3 levels during chronic conditions such as obesity or low-grade inflammation [16].

**5.4. Limitations.** Due to the mainly cross-sectional design of the study, we cannot distinguish if obesity per se or low-grade inflammation is the main driver for the increased fstl3 in obese subjects. Neither are we able to clarify which tissue or tissues are responsible the circulating levels of fstl3 during obesity or inflammation.

TABLE 3: Associations between plasma follistatin-like 3 and biochemical and demographic markers in obese and nonobese subjects.

	Nonobese (BMI < 30) ( $n = 97$ )	Obese (BMI > 30) ( $n = 103$ )
	Spearman's $r$	Spearman's $r$
Age (years)	0.334***	0.350***
Weight (kg)	-0.091	-0.045
Height (m)	-0.164	-0.276**
Hip (cm)	-0.002	0.376***
Waist (cm)	0.079	0.207*
BMI ( $\text{kg}/\text{m}^2$ )	0.128	0.228*
Systolic BP (mmHg)	-0.106	0.046
Diastolic BP (mmHg)	-0.108	0.087
$\text{VO}_{2\text{max}}$ /(mL/min/kg)	-0.149	-0.285***
Whole body fat (kg)	0.312**	0.466***
Trunk fat mass (kg)	0.254*	0.384**
Whole body fat-free mass (kg)	-0.263*	-0.311**
Insulin fasting (pM)	0.292**	0.195*
Glucose fasting (mM)	-0.131	0.138
c-peptide (nM)	0.282**	0.303**
HOMA B	0.342***	0.064
HOMA S	-0.217*	-0.224*
TNF-alpha (pg/mL)	0.334***	0.273**
IL-6 (pg/mL)	0.409***	0.265**
Leptin (pg/mL)	0.386***	0.551***
Adiponectin (ug/mL)	0.168	0.191

Spearman's correlation coefficient is given for each variable. The nonobese group included 97 subjects. The obese group consisted of 103 subjects except for hip (102), waist (102),  $\text{VO}_{2\text{max}}$  (102), and whole body fat (101). HOMA S: homeostasis model assessment of insulin sensitivity. HOMA B: homeostasis model assessment of beta cell function. BMI: body mass index \*indicates a significant correlation between plasma fstl3 and the given variable. \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$ .

## 6. Conclusion

We have demonstrated that circulating levels of fstl3 are increased in obese subjects and that high fstl3 levels are associated with fat mass and markers of low-grade inflammation. The finding that plasma fstl3 was increased in response to TNF- $\alpha$ , but not IL-6, infusion suggests that TNF- $\alpha$  is an inflammatory driver of increased systemic levels of fstl3.

## Conflict of Interests

The authors have no conflicts of interests.

## Acknowledgments

Hanne Viliumsen and Ruth Roving are acknowledged for their technical assistance. The Centre of Inflammation and Metabolism (CIM) is supported by a grant from the Danish National Research Foundation (DNRF55). This study was further supported by the Novo Nordic foundation (TNF- $\alpha$



study). The Centre for Physical Activity Research (CFAS) is supported by a grant from TrygFonden. CIM is part of the UNIK Project: Food, Fitness & Pharma for Health and Disease, supported by the Danish Ministry of Science, Technology, and Innovation. CIM is a member of DD2—the Danish Center for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, Grants nos. 09-067009 and 09-075724). The Copenhagen Muscle Research Centre (CMRC) is supported by a grant from the Capital Region of Denmark.

## References

- [1] S. Hayette, M. Gadoux, S. Martel et al., “FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders,” *Oncogene*, vol. 16, no. 22, pp. 2949–2954, 1998.
- [2] D. L. Allen, A. S. Cleary, K. J. Speaker et al., “Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice,” *The American Journal of Physiology: Endocrinology and Metabolism*, vol. 294, no. 5, pp. E918–E927, 2008.
- [3] Y. Xia, Y. Sidis, and A. Schneyer, “Overexpression of follistatin-like 3 in gonads causes defects in gonadal development and function in transgenic mice,” *Molecular Endocrinology*, vol. 18, no. 4, pp. 979–994, 2004.
- [4] J. J. Hill, M. V. Davies, A. A. Pearson et al., “The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum,” *The Journal of Biological Chemistry*, vol. 277, no. 43, pp. 40735–40741, 2002.
- [5] R. Stämmler, H. T. Keutmann, Y. Sidis, C. Kattamuri, A. Schneyer, and T. B. Thompson, “The structure of FSTL3-activin A complex: differential binding of N-terminal domains influences follistatin-type antagonist specificity,” *The Journal of Biological Chemistry*, vol. 283, no. 47, pp. 32831–32838, 2008.
- [6] L.-E. Zaragosi, B. Wdziekonski, P. Villageois et al., “Activin A plays a critical role in proliferation and differentiation of human adipose progenitors,” *Diabetes*, vol. 59, no. 10, pp. 2513–2521, 2010.
- [7] T. Ueland, P. Aukrust, S. Aakhus et al., “Activin A and cardiovascular disease in type 2 diabetes mellitus,” *Diabetes and Vascular Disease Research*, vol. 9, no. 3, pp. 234–237, 2012.
- [8] H. Wu, M. Wu, Y. Chen, C. A. Allan, D. J. Phillips, and M. P. Hedger, “Correlation between blood activin levels and clinical parameters of type 2 diabetes,” *Experimental Diabetes Research*, vol. 2012, Article ID 410579, 9 pages, 2012.
- [9] D. S. Hittel, J. R. Berggren, J. Shearer, K. Boyle, and J. A. Houmard, “Increased secretion and expression of myostatin in skeletal muscle from extremely obese women,” *Diabetes*, vol. 58, no. 1, pp. 30–38, 2009.
- [10] C. Brandt, A. R. Nielsen, C. P. Fischer, J. Hansen, B. K. Pedersen, and P. Plomgaard, “Plasma and muscle myostatin in relation to type 2 diabetes,” *PLoS ONE*, vol. 7, no. 5, Article ID e37236, 2012.
- [11] D. S. Hittel, M. Axelson, N. Sarna, J. Shearer, K. M. Huffman, and W. E. Kraus, “Myostatin decreases with aerobic exercise and associates with insulin resistance,” *Medicine and Science in Sports and Exercise*, vol. 42, no. 11, pp. 2023–2029, 2010.
- [12] R. Thadhani, C. E. Powe, M. L. Tjoa et al., “First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus,” *Diabetes Care*, vol. 33, no. 3, pp. 664–669, 2010.
- [13] M. L. Brown, L. Bonomi, N. Ungerleider et al., “Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis,” *Obesity*, vol. 19, no. 10, pp. 1940–1949, 2011.
- [14] D. Hu, T. Tian, J. Guo, H. Wang, D. Chen, and M. Dong, “Decreased maternal and placental concentrations of follistatin-like 3 in gestational diabetes,” *Clinica Chimica Acta*, vol. 413, no. 5–6, pp. 533–536, 2012.
- [15] A. Mukherjee, Y. Sidis, A. Mahan et al., “FSTL3 deletion reveals roles for TGF- $\beta$  family ligands in glucose and fat homeostasis in adults,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 4, pp. 1348–1353, 2007.
- [16] M. Y. Donath and S. E. Shoelson, “Type 2 diabetes as an inflammatory disease,” *Nature Reviews Immunology*, vol. 11, no. 2, pp. 98–107, 2011.
- [17] N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” *Nature Reviews Immunology*, vol. 11, no. 2, pp. 85–97, 2011.
- [18] L. Bartholin, S. Guindon, S. Martel, L. Corbo, and R. Rimokh, “Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter,” *Gene*, vol. 393, no. 1–2, pp. 153–162, 2007.
- [19] K. E. Yarasheski, S. Bhasin, I. Sinha-Hikim, J. Pak-Loduca, and N. F. Gonzalez-Cadavid, “Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting,” *Journal of Nutrition, Health and Aging*, vol. 6, no. 5, pp. 343–348, 2002.
- [20] M. Pedersen, K. K. Pedersen, H. Bruunsgaard et al., “Cognitive functions in middle aged individuals are related to metabolic disturbances and aerobic capacity: a cross-sectional study,” *PLoS ONE*, vol. 7, no. 12, Article ID e51132, 2012.
- [21] A. S. Andreasen, M. Kelly, R. M. G. Berg, K. Møller, and B. K. Pedersen, “Type 2 diabetes is associated with altered NF- $\kappa$ B DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS,” *PLoS ONE*, vol. 6, no. 9, Article ID e23999, 2011.
- [22] A. S. Andreasen, N. Larsen, T. Pedersen-Skovsgaard et al., “Effects of *Lactobacillus acidophilus* NCFM on insulin sensitivity and the systemic inflammatory response in human subjects,” *British Journal of Nutrition*, vol. 104, no. 12, pp. 1831–1838, 2010.
- [23] A. S. Andreasen, T. Pedersen-Skovsgaard, R. M. G. Berg et al., “Type 2 diabetes mellitus is associated with impaired cytokine response and adhesion molecule expression in human endotoxemia,” *Intensive Care Medicine*, vol. 36, no. 9, pp. 1548–1555, 2010.
- [24] J. Hansen, A. Rinnov, R. Krogh-Madsen et al., “Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation,” *Diabetes/Metabolism Research and Reviews*, vol. 29, no. 6, pp. 463–472, 2013.
- [25] A. R. Nielsen, P. Plomgaard, K. S. Krabbe, J. S. Johansen, and B. K. Pedersen, “IL-6, but not TNF- $\alpha$ , increases plasma YKL-40 in human subjects,” *Cytokine*, vol. 55, no. 1, pp. 152–155, 2011.
- [26] P. Plomgaard, C. P. Fischer, T. Ibfelt, B. K. Pedersen, and G. Van Hall, “Tumor necrosis factor- $\alpha$  modulates human in vivo lipolysis,” *Journal of Clinical Endocrinology and Metabolism*, vol. 93, no. 2, pp. 543–549, 2008.
- [27] J. Hansen, C. Brandt, A. R. Nielsen et al., “Exercise induces a marked increase in plasma follistatin: Evidence that follistatin is a contraction-induced hepatokine,” *Endocrinology*, vol. 152, no. 1, pp. 164–171, 2011.
- [28] D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment:

- insulin resistance and  $\beta$ -cell function from fasting plasma glucose and insulin concentrations in man," *Diabetologia*, vol. 28, no. 7, pp. 412–419, 1985.
- [29] J. Guo, T. Tian, D. Lu, G. Xia, H. Wang, and M. Dong, "Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsia," *Journal of Obstetrics and Gynaecology Research*, vol. 38, no. 7, pp. 988–996, 2012.
- [30] K. Pryor-Koishi, H. Nishizawa, T. Kato et al., "Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia," *BJOG*, vol. 114, no. 9, pp. 1128–1137, 2007.
- [31] K. Y. Arai, K. Tsuchida, K. Uehara, K. Taya, and H. Sugino, "Characterization of rat follistatin-related gene: effects of estrous cycle stage and pregnancy on its messenger RNA expression in rat reproductive tissues," *Biology of Reproduction*, vol. 68, no. 1, pp. 199–206, 2003.
- [32] P. Miron, J. Lambert, A. Marcil, N. J. Cowans, A. Stamatopoulou, and K. Spencer, "Maternal plasma levels of follistatin-related gene protein in the first trimester of pregnancies with Down syndrome," *Prenatal Diagnosis*, vol. 30, no. 3, pp. 224–228, 2010.
- [33] S. Ebert, D. J. Phillips, P. Jenzewski, R. Nau, A. E. O'Connor, and U. Michel, "Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis," *Journal of the Neurological Sciences*, vol. 250, no. 1-2, pp. 50–57, 2006.
- [34] F. Petraglia, D. De Vita, A. Gallinelli et al., "Abnormal concentration of maternal serum activin-A in gestational diseases," *Journal of Clinical Endocrinology and Metabolism*, vol. 80, no. 2, pp. 558–561, 1995.
- [35] L. Hellström, H. Wahrenberg, K. Hruska, S. Reynisdottir, and P. Arner, "Mechanisms behind gender differences in circulating leptin levels," *Journal of Internal Medicine*, vol. 247, no. 4, pp. 457–462, 2000.
- [36] J. F. McCarthy, D. N. Misra, and J. M. Roberts, "Maternal plasma leptin is increased in preeclampsia and positively correlates with fetal cord concentration," *American Journal of Obstetrics and Gynecology*, vol. 180, no. 3 I, pp. 731–736, 1999.
- [37] K. L. Jones, A. Mansell, S. Patella et al., "Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 41, pp. 16239–16244, 2007.